Complete blood cell counts (CBCs) are one of the most commonly ordered and informative blood tests in hospitals. The results from a CBC, which typically include white blood cell (WBC) counts with differentials, red blood cell (RBC) counts, platelet counts and hemoglobin measurements, can have implications for the diagnosis and screening of hundreds of diseases and treatments. Bulky and expensive hematology analyzers are currently used as a gold standard for acquiring CBCs. For nearly all CBCs performed today, the patient must travel to either a hospital with a large laboratory or to a centralized lab testing facility. There is a tremendous need for an automated, portable point-of-care blood cell counter that could yield results in a matter of minutes from a drop of blood without any trained professionals to operate the instrument. We have developed microfl uidic biochips capable of a partial CBC using only a drop of whole blood. Total leukocyte and their 3-part differential count are obtained from 10 μL of blood after on-chip lysing of the RBCs and counting of the leukocytes electrically using microfabricated platinum electrodes. For RBCs and platelets, 1 μL of whole blood is diluted with PBS on-chip and the cells are counted electrically. The total time for measurement is under 20 minutes. We demonstrate a high correlation of blood cell counts compared to results acquired with a commercial hematology analyzer. This technology could potentially have tremendous applications in hospitals at the bedside, private clinics, retail clinics and the developing world.
INTRODUCTION
Th e complete blood count (CBC) is among the most ubiquitous diagnostic tests in primary and acute care. For example, in acute radiation syndrome (ARS), a CBC test with leukocyte diff erentials is required for the rapid management of the disease 1 . In radiation and chemotherapy, the CBC is routinely performed to observe the necessary cells production by bone marrow to ensure the health of the patient. Infl ammation, leukemia, tissue injury, bone marrow failure and immunodefi ciency can all be identifi ed by irregular leukocytes counts and their diff erentials. Similarly, bone marrow fi brosis, lymphoma, aplastic anemia and lupus erythematosus are associated with abnormal platelet count. Excessive bleeding, kidney bleeding, cancer and mechanical trauma can be accompanied by changes in the RBCs count [1] [2] [3] . Th us, a microfl uidic disposable and economical CBC test could help in monitoring all of these disorders at higher frequency, potentially enabling the diagnosis of diseases much earlier. CBC tests include counting of total WBCs, a fi ve-part diff erential (lymphocytes, monocytes, neutrophils, basophils, eosinophils), RBCs, platelets and their indices (mean cell volume) and hemoglobin concentration. Most commercially available cell counting systems are fl ow cytometers or hematology analyzers [2] [3] [4] . Th e ubiquitous CBC is performed using automated hematology analyzers while fl ow cytometers are used for any specifi c cell counting (e.g., CD4+ T cells or CD8+ T cells for AIDS diagnostics or HIV management) 5 . Hematology analyzers can be both optical and electrical. In commercial systems, the infused blood is fi rst split into two channels. Th e RBCs are then lysed in the WBC counting channel. In optical analyzers, a laser illuminates the cells as they pass through the fl ow cell in a single-fi le manner. Th e scattered light is collected by two photo-detectors. Th e scattered light collected by the photo detector in line with the laser is called forward scatter, and the scattered light collected by the photo-detector perpendicular to the laser is called backscatter. Forward scattered light determines the size of the cells and backscatter gives information on the membrane properties. Th e forward and backscatter plots allow us to diff erentiate total WBCs and their sub-types. In electrical hematology analyzers, the blood cell counting is based on the cell size and membrane properties, which are probed by using kHz to MHz range frequencies with sensing electrodes.
A microfl uidic device capable of enumerating the blood cells from a drop of blood could have tremendous applications ranging from clinical testing laboratories to point-of-care settings [6] [7] [8] [9] . Microfl uidic devices for cell counting have been reported using coulter counters and using AC signals [10] [11] [12] [13] . Holmes et al. has shown the total leukocyte count and its diff erential using multi-frequency analysis 7 . Most of the above mentioned microfl uidic counters were based on impedance cell counting technology 14, 15 . Nguyen et al. have also characterized a biochip for CBC; however, the study lacks comprehensive diff erential counts, demonstrates only a small number of samples for statistical validation, and reports a small dynamic range of cell counts of blood samples 16 . Recently, Smith et al. have also shown an image-based device for complete blood cell counts with off -chip sample preparation 17 . However, the translation of their optical device to a portable system will have illumination non-uniformity and higher noise issues that they also mentioned in their article 17 . In our previous studies, we have also characterized in detail our microfl uidic impedance sensors to count CD4 and CD8 T cells for HIV diagnostics using a diff erential capture technique 18, 19 . We have also characterized the coincidence eff ects in our counter 20 and performed a detailed mathematical characterization of the electrical cell counting process 21 .
In this current study, we report a comprehensive characterization of blood cell counting including total leukocytes and their three-part diff erentials, RBCs and platelet count. We demonstrate the operation of the device for a wider dynamic range of cell counts, including blood samples collected from patients admitted to a non-coronary Intensive Care Unit (ICU) at the Carle Foundation Hospital, Urbana, IL. Th e immune system of the ICU patients is oft en highly compromised and we were able to demonstrate a leukocyte dynamic range from as low as 200 cells/μL up to around 15,000 cells/μL. We also collected blood samples from cancer patients undergoing chemotherapy (anemic patients) and using our chip, we were able to show that these patients have signifi cantly lower RBC and platelets counts when compared to healthy donor samples. Our blood cell counter exhibits the potential to improve patient care in a wide spectrum of medical settings.
METHODS AND MATERIALS

Experimental approach
A schematic illustrating the overall approach for a chip capable of WBC counts (three-part differential), RBC counts and platelet counts is shown in Fig. 1 . We begin with a drop of blood typically around 50 μL in volume. From this, we meter out 11 μL of blood off -chip using an automated switching valve to input to the chips (Supplementary Fig. 1 ). Since electrical differentiation of the cells is primarily based on size differences, platelets and RBCs can be diff erentiated electrically, and the lymphocytes can be diff erentiated from other types of WBCs based on the observed pulse amplitude. Two separate chips were used to obtain the three-part WBC diff erential and the RBC/ platelet counts. For WBC counts, the infused blood is exposed to the lysing and quenching solutions to eliminate the RBCs from the solution. As shown in the top path in Fig. 1 , the solution now contains a mix of WBCs, including neutrophils (60%), lymphocytes (30%), monocytes (7.5%), eosinophils (3%) and basophils (<0.5%). Since fewer than 10 basophils are present per μL of blood, basophils will not be counted and can be ignored for the proof of concept experiments. Th e solution is then fl owed through the electrical counter of the chip, resulting in a count that contains lymphocytes, neutrophils, monocytes and eosinophils. At this point, a total lymphocyte count can be extracted since the lymphocytes can be separated based on their diff erent pulse amplitudes. Th e remaining cells are grouped into a population consisting of neutrophils, monocytes and eosinophils. Neutrophils can be diff erentiated further from monocytes and eosinophils based on their membrane properties that is refl ected by the impedance change at high frequencies (greater than 1 MHz) 22 ( Supplementary Fig. 2) .
For RBC and platelet counts (lower path in Fig. 1 ), a dilution of the blood is necessary because the concentration of RBCs is extremely high, i.e., about fi ve million cells per μL in healthy human blood samples. Th e dilution factor will need to be optimized to maintain accurate counts without increasing the test time signifi cantly. Aft er dilution, the RBCs and platelets can be counted using the same counting electrodes due to their diff erence in size.
Electrode design for accurate cell differentiation
Electrode design is important to properly diff erentiate between diff erent cell types, e.g., lymphocytes from granulocytes + monocytes. A schematic of the WBC counting chip is shown in Fig. 2 . Th e microfabricated platinum electrodes are aligned within the 15 μm × 15 μm aperture crosssection 21 . Blue circles represent typical leukocytes. A schematic of the sensing region is shown in Fig. 2b . Th e red circle represents a leukocyte in the middle of the two electrodes. Th e output voltage of the sensing region is measured as A-B. Th e peak of the voltage ' A' will occur when the cell is exactly in the middle of the fi rst two electrodes. Two relevant cases exist. In the fi rst case, the spacing between the electrodes is greater than the cell diameter such that no portion of the cell is present over the second electrode, when the cell is in the middle of fi rst two electrodes. Th e output voltage B will be zero in this case and the maximum pulse amplitude will be preserved. In the second case, the spacing between the electrodes is smaller than the cell diameter. When the cell is in the middle of fi rst two electrodes, a portion of the cell will be over the second electrode, thus producing the output voltage B > 0. Th e resulting diff erential signal A-B will lose the maximum amplitude of the pulse that corresponds to the cell size. Th us, for diff erentiating between diff erent cell types, the electrode spacing should be greater than or equal to the maximum cell diameter that needs to be diff erentiated.
In order to eff ectively diff erentiate between lymphocytes, granulocytes and monocytes, the electrode spacing should be at least 15 μm, as the diameter of the granulocytes/monocytes ranges from 12-15 μm. Th e pulses obtained as the leukocytes pass over the counting electrodes are shown in Fig. 2c . Th e amplitude of the pulse is proportional to the size of the cell. Supplementary Fig. 3 shows the cell voltage pulse amplitude histogram obtained with the sensing region consisting of the 5 μm spacing and width of the electrodes. Electrode spacing is less than the size of the cells, resulting in less accurate cell diff erentiation between lymphocytes and granulocytes + monocytes. Th e cell voltage pulse amplitude histogram was obtained with a sensing region consisting of the 15 μm spacing and width of the electrodes (Fig. 2d) . Electrode spacing is greater than the size of the cells, resulting in more accurate cell diff erentiation.
Reagents
• Lysing buff er: 0.12% (v/v) formic acid and 0.05% (w/v) saponin in DI.
• Quenching buff er: 21.1785% v/v 10 × PBS + 2.301 g of sodium carbonate in DI water.
• Blood is diluted with 1× PBS (pH = 7.4) at diff erent dilution factors for RBC and platelet counting.
Blood sample acquisition
Blood samples were drawn from healthy donors via venipuncture through an Institutional Review Board (IRB) consent process. ICU blood samples were collected from the Carle Foundation Hospital and were brought to the Micro and Nanotechnology Laboratory at the University of Illinois at Urbana-Champaign for the cell counting experiments. Th e blood samples were collected in EDTA-coated BD vacutainers and were kept at room temperature on a rotisserie. Experiments were performed within 6 hours of blood draw.
Chip fabrication
Th e negative master mold of the fl uidics regions, including lysing, quenching and counting, were created by patterning an SU8-50 negative photoresist on the Si wafer. Th e surface of the Si-mold was salinized using 3-mercaptopropyltrimethoxysilane 20, 21 . A mixture of polydimethylsiloxane (PDMS) is mixed with the curing agent with a ratio of 10:1 and is poured on the Si-mold that is then cured for 30 minutes at 90°C. Th e platinum electrodes are fabricated by patterning the negative of the electrodes on a Glass/Pyrex wafer using LOR3A and S-1805 photoresists. CD-26 developer is then used to develop the wafers. An adhesion layer of 25-nm titanium is evaporated which is then followed by 75 nm of platinum deposition 20, 21 . Wafer is kept in Microchem PG remover for 20 min at 70°C to remove the undesired metal.
Power analysis
Power analysis is used to determine the sample size required to get the desired statistical values. In order to get the correlation coeffi cient, ρ = 0.9 we selected an alpha level (two tailed) of 0.01 and power at 0.9. For ρ = 0.9, Z α = 2.58. However, Z b = 1.28 for the desired 0.9 power level. Th e following equation is used to calculate the required sample size, which gives N = 13.
( ) 
Equipment used
Lysing and quenching buff ers are infused with an Eksigent Nanofl ow LC pump with precise fl ow rates. Metered volume of the blood sample was loaded into the chips using a Rheodyne MHP7980-500-1 valve. Input voltage signal was fed to the microfabricated electrodes using Zurich Instruments HF2LI lock-in amplifi er. Th e voltages diff erence between © World Scientific Publishing Co./Imperial College Press the electrodes was obtained by using the Zurich Instruments diff erential preamplifi er HF2CA. Th e output signal from the lock-in amplifi er is sampled using the PCI-6351 DAQ card (National Instruments). A customized Matlab program is written to perform the data analysis.
RESULTS AND DISCUSSION
Total WBC and three-part differential count Erythrocytes are lysed by infusing lysing buff er in the microfl uidic biochip. Aft er the erythrocyte lysis the cell debris tends to clump and make "debris ghosts" which result in clogging of electrical cell counting aperture of 15 μm × 15 μm. Th e debris clump also produces an appreciable change in impedance and would result in background baseline voltage noise. In our previous study, we found that greater quenching time of about 48 seconds results in providing the shear stress long enough to disassociate the erythrocyte debris clumps 18 . However, adding the 48-second step in the biochip would not only increase the size of the chip but also result in high fl uidic resistance of the biochip. Saponin helps in dissociating the debris.
Th e blood was lysed on-chip with a blood:lysing ratio of 1.75:12. Th e lysing time was optimized for 9 seconds. Th e lysing process was halted as the quenching buff er composed of sodium carbonate and PBS is mixed with the solution. Th e blood to quenching ratio was then adjusted to 1.75:10. Th e prepared solution was passed through the microfabricated platinum electrodes of 15 μm width and 15 μm spacing. Th e input signal to the electrodes was 7 V and 303 kHz is multiplexed with 1.7 MHz. Th e data were acquired at the sampling frequency of 500 kHz. Th e amplitude histogram of all the leukocyte voltage pulses is shown in Fig. 3a . It shows the distinct separation of the lymphocytes and granulocytes + monocytes. Voltage thresholds for cell counting were selected manually considering the minima in between debris and lymphocytes and lymphocytes and granulocytes + monocytes. We compared the biochip counts with the control count using 10 blood samples collected from patients admitted to the ICU (shown in red) and 13 blood samples from non-ICU donors (shown in blue). Th e comparison of the biochip total WBC counts with control counts is presented in Fig. 3b . Th ere is a good correlation between the two methods with R 2 = 0.95 and with total WBC recovery of 68.35%. Th e comparison of biochip total lymphocyte count with the control count is shown in Fig. 3c . It also shows a good correlation between the two methods with R 2 = 0.96 and with total lymphocyte recovery of 71.83%. Th e comparison of biochip total granulocyte + monocyte count with the control count is presented in Fig. 3d . It shows a good correlation between the two methods with R 2 = 0.96 and with total granulocyte + monocyte recovery of 68.02%.
Precision studies of WBC and differential counting
Repeated experiments were performed from a single blood sample to measure the precision of our cell counting experiments. Th e precision study for the total WBC, lymphocyte and granulocyte + monocyte counts from biochip in comparison with the control counts from the hematology analyzer is shown in Fig. 4 . Th e diff erent-colored bars represent the mean, and the error bars represent the standard deviation of the cell recoveries for samples A, B and C with 7, 8 and 9 repeated experiments, respectively.
Differentiating neutrophils from other granulocytes
To diff erentiate between neutrophils vs. monocytes + eosinophils, we fi tted the lognormal distribution to the high frequency (1.7 MHz) histogram of the granulocyte + monocyte population as shown in Supplementary  Fig. 4 . Non-ICU samples were selected for this study. Th e skewness of the fi tted lognormal distribution to the high frequency granulocyte + monocyte histogram is linearly correlated with the control monocyte + eosinophil concentration with an R 2 = 0.83 as shown in Fig. 5a . Equation (2) is used as a calibration to calculate the biochip monocyte + eosinophil concentration from the skewness of the fi tted lognormal distribution to the high-frequency histogram of granulocyte + monocyte population. Th e comparison of the control monocyte + eosinophil count with the biochip's calculated monocyte + eosinophil using Equation (2) as a fi t factor, is shown in Fig. 5b . Th is provides a good correlation with an R 2 = 0.80. 
where Biochip Mono. + Eosino. count were obtained from Equation (2) and 0.68 value represents the recovery of the total granulocyte + monocyte population with low frequency. Th e comparison of the control neutrophil count with the calculated biochip neutrophil count is shown in Fig. 5c . Th e biochip neutrophil count is calculated using Equation (3). Th ere is a good correlation with R 2 = 0.82 and neutrophil recovery of 63.38%. Th e percentage of the total neutrophils comprising total granulocyte + monocyte should remain constant between control results and results calculated from biochip counts. Th e comparison of the neutrophil percent of the granulocyte + monocyte concentration from the control results with the calculated biochip neutrophil percentage is shown in Fig. 5d . Th ere is a good correlation with R 2 = 0.80. To further validate neutrophil counts obtained from the skewness analysis, we performed a control experiment in which lysed blood output was collected from the biochip. Th e sample was conjugated with CD66b fl uorescent antibody (this antibody is specifi c to the neutrophils). Aft er running it from fl ow cytometer, the neutrophil population was gated on the fl uorescent vs. side scatter plot (Supplementary Fig. 5) . Th e resulting neutrophil counts were compared with our electrical neutrophil counts obtained from skewness analysis. Th e analysis was done for three samples and the % error obtained was 5.2%, 3.7% and 6.1% respectively.
Electrical counting of erythrocytes and platelets
Optimization of electronic settings and digital signal fi ltering Platelets, being the smallest (~1-2 μm diameter) of all the blood cell types, are the most diffi cult to measure. To measure the platelets and the RBCs, the blood was diluted off -chip with PBS with a ratio of 1:300. Th e diluted blood was passed through the counting electrodes at 40 μL/min and the data was sampled at 1 Ms/sec. Th e sensing region of the counting electrodes was reduced to 5-μm spacing and width of electrodes with the same channel aperture of 15 μm × 15 μm resulting in higher sensitivity. Th e amplitude histogram of the voltage pulses obtained is shown in Fig. 6 . We varied the voltage and gain settings to acquire the platelets signal. Th e amplitude histogram of the voltage pulses was obtained as the cells in the diluted blood are passed through the counting region (Fig. 6a) . Th e input voltage is set to 5 V with a diff erential amplifi er gain of 10 . Th e red arrow shows the zoomed-in version of the black dotted rectangle, which shows a smooth decrease of RBC distribution. Th e histogram with the input voltage of 10 V and a diff erential amplifi er gain of 10 was obtained (Fig. 6b) . Th e zoomed-in version shows an appearance of platelet distribution to the left of the RBC distribution. A typical voltage pulse corresponding to the RBC is shown in Fig. 7 with signal-to-noise ratio (SNR) of 21.7 dB. A typical voltage pulse corresponding to the platelet with an SNR of 11.4 dB is shown in Fig. 7 . In order to obtain the maximum SNR for the pulses, the input voltage to the electrodes is varied from 1-10 V. Supplementary  Fig. 6 shows the corresponding increase in the mean SNR of the RBC pulses with the increase in the input voltage. It shows a linear increase with an R 2 value of 0.86. Th e frequency spectrum of the cell counting experiment data will allow us to observe the noise components in the frequency domain. Supplementary Fig. 7 shows the frequency spectrum of the entire cell counting data without performing any digital fi ltering. Th ere is lowfrequency noise in the data because of the baseline drift s, electronic noise and power-line interference (60 Hz). Most of the cells pulses spectrum lies in the range of 5-90 kHz as shown in Supplementary Fig. 7a . Th ere is an input frequency noise of 303 kHz and another high-frequency noise at 314.8 kHz as shown in Supplementary Fig. 7b . Th ese can be removed by using a low-pass fi lter with cut-off -frequency less than 303 kHz.
Th e low-frequency noise in the data is removed by applying a highpass fi lter with cut-off frequency of 20 Hz. To remove the power line frequency, a band-stop fi lter is used with cut-off frequencies of (58, 62) Hz. Th e second harmonic of the power line frequency is also removed using a band-stop fi lter with cut-off frequencies of (118, 122) Hz. Th e baseline drift is also corrected. The frequency spectrum of the cell counting experiment data aft er signal fi ltering is shown in Supplementary Fig. 8 .
RBC and platelet counting with off-chip dilution
Th e erythrocyte (RBC) concentration in the blood sample is signifi cant and thus requires dilution for accurate cell counting. Th e RBCs can be 
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diff erentiated from platelets and WBCs from the electrical voltage pulse's amplitude histogram as the RBC is bigger than a platelet but smaller than a WBC. Th e blood samples were diluted off -chip with diff erent blood:PBS dilution ratios. We fl owed the diluted blood sample through our impedance cell counter and count all the pulses; the sample contains RBCs, platelets and all WBCs. Th e leukocytes comprise about 0.5% and platelets about 3-5% of the erythrocytes, and aft er dilution the leukocyte concentration in the sample becomes very low -around 50 cells/μL, resulting a negligible eff ect on the counting results. Th e control RBC counts were compared with the counts obtained from the biochip using 22 blood samples (Fig. 8a) . Blood is diluted with PBS at diff erent dilutions (PBS:blood) and fl owed through the biochip. It shows a good correlation between the two methods with R 2 = 0.96 and the cell recovery of 96.35%. Th e cases for which the biochip noise is higher; platelet distribution did not appear. Th e noise comparison of the biochips for platelet counting is given in 'Discussion' section. Th e control platelet counts were compared with the counts obtained from the biochip using 13 blood samples (Fig. 8b) . It shows a good correlation in between the two methods with R 2 = 0.84 and the cell recovery of only 51%. Th e decrease in the cell recovery can be associated with the high noise in the biochip, resulting in loss of platelet pulses in the noise. Platelets, being the smallest (~1-2 μm diameter), result in small impedance change.
Precision studies of RBC and platelet counting
Repeated experiments were performed from a single blood sample to measure the precision of our RBC-and platelet-counting experiments.
Blood is diluted with PBS with a ratio of 1:200 and fl owed at 40 μL/ min through the electrical counter. Th e precision results of RBC-counting are shown in Fig. 9a. '1' shows the healthy donor sample with a CV = 2.6% for fi ve repeated experiments; '2' shows a cancer donor sample with a CV = 5.5% for fi ve repeated experiments; and '3' shows another cancer donor sample with a CV = 5.8% for four repeated experiments. Th e precision results of RBC-counting are shown in Fig. 9b . '1' shows the healthy donor sample with a CV = 10.2% for fi ve repeated experiments; '2' shows a cancer donor sample with a CV = 8.1% for fi ve repeated experiments; and '3' shows another cancer donor sample with a CV = 9.3% for four repeated experiments.
RBC and platelet counting with on-chip dilution
Th e on-chip dilution is performed on the biochip; the schematic is shown in Fig. 10 . Th e PBS and the blood are infused in the biochip at the indicated inlet ports. Th e PBS is mixed with blood at the ratio of 40:0.5 μL/min in the serpentine channels. Th e electrical counter counted the cells in the diluted blood as they pass through the electrodes. In order to improve the SNR the width and spacing of the electrodes was reduced to 5 μm.
The Blood is diluted on-chip with PBS with flow rate ratio (blood: PBS = 0.5:40 μL/min). The resulting diluted blood is flowed through the electrical counter. The control RBC counts are compared with the counts obtained from the biochip using 21 blood samples (Fig. 11a) . It shows a good correlation between the two methods with R 2 = 0.82 and the cell recovery of 93.52% after coincidence correction. The decrease in the cell recovery can be associated with the high number of coincidences at the low dilution factor. The control platelet counts are compared with the counts obtained from the biochip using 13 blood samples (Fig. 11b) . It shows a good correlation between the two methods with R 2 = 0.90 and the cell recovery of 67.85%. The decrease in the cell recovery can be associated with the high number of coincidences at the low dilution factor and loss of the platelets pulses in the noise. 
DISCUSSION
Our sensor has the potential to be translated to a commercial pointof-care CBC biochip. However, being in early stages of development, there is much room to further improve the parameters including cell recovery, voltage thresholds for cell counting, electrodes confi guration and skewness analysis for more sensitive and accurate results. Currently, threshold selection for the cell counting is performed manually while considering the minima between diff erent populations. However, in a portable and completely automated CBC counter, this can be done using an automated algorithm considering two parameters, i.e., minima in between two distributions and a preselected threshold value which will be much more precise in mass manufactured cartridges and electrodes. Th e variability in the biochip fabrication in the current research settings can be a limitation when it comes to achieving consistent properties and geometries of the electrodes. For example, the variability in the selected threshold value for total WBC counting was approximately 30% (Supplementary Information). In point-of-care automated cell counters, the threshold selection can be automated since the cartridges/electrodes will be commercially manufactured and the fabrication process is expected to be more consistent and streamlined.
Microfl uidic biochips utilize an aggressive lysing step to ensure the lysing of the RBCs as the desired time to perform this lysing should be small. Hematology analyzers use lysing reagents that result in lysing/quenching time in the order of 10 minutes. In point-of-care microfl uidic biochips, using these regents with signifi cant higher times will result in unacceptably large assay time and use of extra reagent volumes. Th is will also result in a much higher footprint of the device, thus directly aff ecting the cost per assay. However, with our rapid lysing solution to eff ectively lyse all erythrocytes and to ensure the complete dissociation of RBC debris clumps (to prevent clogging of the chips; one of major problem in point-of-care biochips), the lysing solution resulted in loss of leukocytes as well.
In experiments for which we were able to see the platelet distribution; the standard deviation of the noise was less than 0.03 V. Th e baseline drift in the signal also got completely removed aft er the fi ltering and baseline correction algorithm as shown in Supplementary Fig. 9 . However, for the experiments for which we were not able to see the platelet distribution, the standard deviation of the noise in the biochip is greater than 0.05 V. Also the baseline drift was very large compared to the good chips as shown in Supplementary Fig. 10 .
Th e signal averaging technique can be used to improve the SNR that only works if the noise is Gaussian white noise and not pink or brown noise having spectral characteristics of 1/f and 1/f 2 , respectively. We have shown the decrease in the standard deviation of chip noise with signal averaging. PBS is fl owed through the electrical counter at 40 μL/min and the chip noise is recorded. Th e measured standard deviation of the chip noise was 0.0873 V. Supplementary Fig. 11 shows the decrease in the standard deviation of the chip noise with signal averaging. Increased number of samples for averaging will result in decreased standard deviation for the chip noise. Aft er averaging with two samples, the standard deviation is reduced to about 0.06 V, which further decreased to 0.04 V aft er signal averaging with three samples. Platelets are 1-2 μm in size as compared to the channel cross-section of 15 μm × 15 μm. Any platelets fl owing at the top of the channel might get lost in noise. Th is can be remedied by using hydrodynamic focusing 23 . For this we need to redesign the channel accordingly or introduce another buff er, which will not be desirable for a point-of-care device, where one objective is to minimize the number of reagents.
Aft er performing the high-pass fi ltering at 20 Hz and power-line fi ltering at 60 and 120 Hz, the frequency spectrum of the RBC, platelet counting experimental data with the sampling rate of 1 MHz and input signal frequency of 303 kHz are obtained and shown in Fig. 6 . The red arrow shows voltage pulse frequency spectrum. Th e green arrow shows a peak at 303 kHz, which can be further removed to decrease the chip's noise. A low-pass fi lter of 200 kHz can be used to remove this noise. Th e standard deviation of the chip noise without using this fi lter were able to isolate the granulocytes from monocytes with top-bottom electronic confi guration that is more sensitive than our co-planar electrodes confi guration 7 . However, top-bottom electrodes confi guration may impose some developmental challenges like alignment of electrodes within a few microns and electronic connectors arrangements from both layers, resulting in more complicated and potentially expensive cartridges.
Th e blood samples collected from the ICU patients sometimes have abnormally high number immature granulocytes ranging from 10-2,200 cells/μL as compared to 10-20 cells/μL in healthy samples. Th e high number of immature granulocytes will result in changing the skewness level of the fi tted lognormal distribution. Th us, the regular correlation of skewness with the control monocyte + eosinophil count does not hold with high number of immature granulocytes. When we fi tted bimodal distributions to the impedance histograms at high frequency (using maximum likelihood optimization for parameter estimation in Matlab), the fi tting function was unable to converge or produced erroneous fi tting values for cases where the monocytes population was less than <10% of leukocytes. Our results were obtained for monocytes + eosinophils population comprising of 8.5-16% of total leukocytes.
RBC recovery is signifi cantly higher in our biochip; however WBC recovery of ~65% is acceptable only if the precision of the test is good, and the percent recovery can be used as a correction factor to get the accurate counts 24 . However, for platelet counts we do realize that currently the recovery is low, i.e., ~50-60%. Th is can be further improved by various techniques as we discussed above. Also, the current work presents two separate chip modules for RBC/platelet counting and WBCs and its diff erential counting. However, both of these modules can be easily integrated into a single cartridge. For research purposes, the split modules allowed us to characterize, debug and run experiments in a detailed fashion.
Th e experiments were performed with diff erent patient populations and over a large dynamic range. Th e standard deviation in the recoveries of WBCs, lymphocytes and granulocytes + monocytes we obtained were 8.12%, 13.11% and 8.89%, respectively. Th e variability in recovery of cell counts can be attributed to many factors including the uncontrolled temperature and humidity environment of our experiments, variability in the fabrication of cartridges that result in diff erent SNR measurements from the setup, etc. In addition, there can be an inherent variation in cell counts across diff erent instruments from same manufacturers. Th e current variability in the recovery results can be further reduced with more standardized processes of fabrication and a controlled environment in a point-ofcare counter.
T h e a p p l i e d voltage used in the erythrocyte counting experiments is up to 10 V. Th e electrolysis of the cells depends on many factors including applied voltage and whether it is DC or AC, the frequency of the applied voltage, fl ow rate of the cells and the critical time for irreversible electroporation [25] [26] [27] . If the actual transmembrane voltage increases well above 1 V, then electroporation can begin to happen 25 . In our experimental conditions, with 10-V peak voltage at frequency of 303 kHz, and using intracellular resistivity reported in literature, the resulting transmembrane potential can be calculated to be around 2 V. So looking at transmembrane potential only, we would be above the critical voltage to cause cell lysing. However, the electroporation (and irreversible electroporation and cell lysing) is also critically dependent on the time that the cells are exposed to the electrical fi eld. Th e reported critical time for electrical lysis of erythrocytes can vary anywhere between 100 μs to a few milliseconds 25 . In our case, with the fl ow rates used in our experiments, the pulse width across two electrodes is approximately 50 μs. During this 50 μs, the cell is exposed to diff erent electric fi eld strengths at diff erent times during the fl ow path over the electrodes. However, electroporation might have happened to the erythrocytes resulting in damaging the cell membranes. Hence, it is certainly likely that the SNR increase is not only due to increased voltage itself, but also due to electroporation or partial cell lysis resulting from the increased electric fi eld. It however does not cause an error in the cell counting, which is the primary goal of our paper.
A portable CBC device exhibits the potential to improve patient care in a complete spectrum of settings. One of the most compelling possibilities is in resource-limited settings where laboratory tests are oft en inaccessible due to cost, poor laboratory facilities and the diffi culty of follow-up upon receiving results that take days to process. Ease-of-use and the ability to interface with mobile communication devices such as smartphones and tablets with wireless internet connectivity enable a point-of-care device by which rapid results can be transmitted to a provider anywhere in the world, eliminating the need for a highly trained professional at the site of care and thus reducing the cost.
Th e wireless delivery of results to healthcare providers also enables use of the device in the home setting, particularly for patients with chronic conditions or those undergoing continued therapy that requires the monitoring of any one or multiple components of a CBC and WBC differential. Rapid results in a portable device carried on an ambulance will shape interventions in pre-hospital care and provide receiving emergency departments with CBC results upon arrival. When transport time is signifi cant such as in rural settings, the CBC can provide an assessment of patient stability and can provide information to advise emergency medical technicians on further care.
In the emergency department, a rapid CBC device promises faster results than the current capabilities of clinical laboratories and will decrease laboratory workload. It not only may speed up life-saving care in emergent cases, but also may improve emergency room throughput and ultimately decrease waiting time in busy hospitals. Upon a patient's admission to full hospital care, this device can be used at the bedside to monitor the patient regularly in the hospital room, especially a patient in an ICU. Finally, this device can be used in the physician's offi ce during regular visits for basic screenings or follow-up examinations that require blood counts to be performed.
SUPPLEMENTARY INFORMATION
Volume metering Supplementary Fig. 1 shows the volume metering method used to meter and fl ow a specifi c desired blood volume into the biochip. An Eksigent HPLC system is used to pump the reagents at the specifi c fl ow rates. Lysing and quenching reagents are directly infused into biochip at their respective inlet ports. An injection valve (two-position, six-port) connected to 10 μL tubing (volume of tube is adjusted to required volume) is used to meter out the desired blood volume. In fi rst step, blood is infused into the measurement tubing; it fi lls it up and goes to the waste (path 'a'). During second step, the valve is switched to path 'b' electronically and PBS starts to push the metered blood into the biochip. Th e volumes of the tube used for white blood cells (WBCs), its diff erential counting and red blood cells (RBCs), platelet counting are 10 and 1 μL, respectively.
Supplementary Figure 2 The simplifi ed electrical model of a cell. the impedance change is based on the cell size, since at these frequencies cells behave as a non-conducting fl uid. At frequencies greater than 1 MHz, the change in impedance is based on diff erent structural properties of the plasma membrane. At frequencies higher than 100 MHz, the change in impedance is based on the nuclear membrane properties. Th us, cells can be diff erentiated based on their sizes, plasma membrane and nuclear membrane structures. 22 To validate the neutrophil count obtained aft er the skewness analysis, the lysed blood output of the chip is collected and conjugated with fl orescent CD66b antibody (specifi c to the neutrophils). Th e sample is Supplementary Fig. 2 shows the electrical model of the cell. R c1 is the resistance of the plasma membrane (100 MΩ), which is highly resistive to the fl ow of charges. C m is the capacitance of the plasma membrane. R c2 is the resistance of the cytoplasm, which comes in contact with the nucleus with nucleoplasm resistance, R n . Th e capacitance of the nuclear membrane is represented by C n and is approximately half of the membrane capacitance, since it is composed to two lipid bilayers.
Theoretical analysis
At low frequencies, the input voltage appears at the plasma membrane, due to the plasma membrane resistance. At frequencies of about 100 kHz, 
